{"id":"acp-104","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL4297687","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By acting as an inverse agonist, ACP-104 decreases histamine signaling in the brain, which may help regulate sleep-wake cycles and improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or other conditions.","oneSentence":"ACP-104 is a selective histamine H3 receptor inverse agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:18:46.990Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Excessive daytime sleepiness in patients with narcolepsy or other conditions"}]},"trialDetails":[{"nctId":"NCT00490516","phase":"PHASE2","title":"ACP-104 in Acutely Psychotic Subjects With Schizophrenia","status":"COMPLETED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2007-06","conditions":"Schizophrenia","enrollment":247},{"nctId":"NCT00628420","phase":"PHASE1","title":"Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2005-01","conditions":"Schizophrenia","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ACP-104","genericName":"ACP-104","companyName":"ACADIA Pharmaceuticals Inc.","companyId":"acadia-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ACP-104 is a selective histamine H3 receptor inverse agonist. Used for Excessive daytime sleepiness in patients with narcolepsy or other conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}